Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3629706 | 0.75 | DRD2 (0.58) | LMNAMAPTHTTALDH1A1POLB | |
| SCHEMBL1447953 | 0.74 | — | — | |
| SCHEMBL10498542 | 0.74 | LMNA (0.70) | LMNAMAPTGAAHTTALDH1A1 | |
| SCHEMBL6663539 | 0.74 | — | — | |
| SCHEMBL3910170 | 0.73 | LMNA (0.57) | LMNAMAPTKMT2AMEN1 | |
| SCHEMBL2633644 | 0.72 | MEN1 (0.54) | LMNAMAPTALDH1A1POLBTSHR | |
| SCHEMBL3897739 | 0.72 | LMNA (0.57) | LMNAMAPTGAAHTTALDH1A1 | |
| SCHEMBL9286378 | 0.70 | LMNA (0.59) | LMNAMAPT | |
| SCHEMBL27521550 | 0.69 | LMNA (0.53) | LMNAMAPTGAAHTTALDH1A1 | |
| SCHEMBL8957619 | 0.69 | LMNA (0.45) | LMNAMAPTGAAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516383-B1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-8691839-B2 | Aminotetraline derivatives | GMEINER PETER (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20130331429-A1 | AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2013-12-12 | — | — | US | disclosed |
| US-8586603-B2 | Aminotetraline derivatives | GMEINER PETER (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120277262-A1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2516383-A1 | NEW AMINOTETRALINE DERIVATIVES | Gmeiner, Peter (DE) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076708-A1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338873-A1 | New aminotetraline derivatives | Gmeiner, Peter (DE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277262-A1 | NEW AMINOTETRALINE DERIVATIVES | AADAT, ABAT, AANAT | LMNA 1699/4885MAPT 130/4885GAA 2312/4885 |
| US-20130331429-A1 | AMINOTETRALINE DERIVATIVES | AADAT, ABAT, SLC1A2 | LMNA 2868/4885MAPT 58/4885GAA 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.